Multiple Myeloma also known as Kahler’s disease is a type of blood cancer that affects plasma cells a subtype of white blood cells. Plasma cells are antibody generating cells. When an individual suffers from multiple myeloma these plasma cells produce immunoglobins in excess which damage the other organs of the body. Multiple Myeloma is usually rare and based on the effect on the body it is categorized into two: an indolent myeloma, usually develops slowly and doesn’t cause bone tumors. There is only slight increase in (monoclonal) M plasma cells and protein, and a solitary plasmacytoma, typically form tumors in bone. Multiple myeloma is not curable and treatment can only slow down the cancer progression. However, CAR T-Cell therapy is a novel therapy which make use of genetically engineered T cell to make chimeric antigen protein which in turn identify the target protein on cancerous cells and kill them. CAR T-cell treatments for multiple myeloma target a protein called B-cell maturation antigen (BCMA), present on the surface of myeloma cells but not healthy cells.
DelveInsight’s, “CAR T-Cell Therapy for Multiple Myeloma Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for free Sample Report: https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight
Some of CAR T-Cell Therapy for Multiple Myeloma Companies are:
- Novartis
- Janssen Biotech
- Yake Biotech
- Celgene Corporation
- And Many Others
Request for free Sample Report: https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight
DelveInsight’s CAR T-Cell Therapy for Multiple Myeloma report covers around 5+ products under different phases of clinical development like:
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
CAR T-Cell Therapy for Multiple Myeloma Therapies are:
- PHE 885
- JNJ-68284528
- And Many Others
Current CAR T-Cell Therapy for Multiple Myeloma Treatment Scenario and CAR T-Cell Therapy for Multiple Myeloma Emerging Therapies:
- How many companies are developing CAR T-Cell Therapy for Multiple Myeloma drugs?
- How many CAR T-Cell Therapy for Multiple Myeloma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T-Cell Therapy for Multiple Myeloma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Multiple Myeloma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CAR T-Cell Therapy for Multiple Myeloma and their status?
- What are the key designations that have been granted to the emerging drugs?
Request for free Sample Report: https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight
Table of Contents:
Introduction
Executive Summary
CAR T-Cell Therapy for Multiple Myeloma: Overview
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
CAR T-Cell Therapy for Multiple Myeloma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
CAR T-Cell Therapy for Multiple Myeloma Collaboration Deals
Early Stage Products (Phase I)
PHE 885: Novartis
Drug profiles in the detailed report…..
Pre-clinical Stage
JNJ-68284528: Janssen Biotech
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug profiles in the detailed report…..
Inactive Products
CAR T-Cell Therapy for Multiple Myeloma Key Companies
CAR T-Cell Therapy for Multiple Myeloma Key Products
CAR T-Cell Therapy for Multiple Myeloma- Unmet Needs
CAR T-Cell Therapy for Multiple Myeloma- Market Drivers and Barriers
CAR T-Cell Therapy for Multiple Myeloma- Future Perspectives and Conclusion
CAR T-Cell Therapy for Multiple Myeloma Analyst Views
CAR T-Cell Therapy for Multiple Myeloma Key Companies
Appendix
Request for Detailed TOC @ https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight